4D Molecular Therapeutics

General Information
Business:

 

We are a development-stage precision gene therapy company dedicated to pioneering the development of targeted therapies based on our next-generation AAV vectors. Our proprietary Therapeutic Vector Evolution platform enables our “disease first” approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the underlying disease.

(Note: The 4D Molecular Therapeutics IPO was upsized at pricing: 8.4 million shares were priced, up from 7.0 million shares in the prospectus. The IPO price was $23, the top of the new increased price range of $22 to $23 for the deal.)

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 57
Founded: 2013
Contact Information
Address 5858 Horton Street #455, Emeryville, CA 94608, US
Phone Number (510) 505-2680
Web Address http://www.4dmoleculartherapeutics.com
View Prospectus: 4D Molecular Therapeutics
Financial Information
Market Cap $536.2mil
Revenues $13.5 mil (last 12 months)
Net Income $-20.9 mil (last 12 months)
IPO Profile
Symbol FDMT
Exchange NASDAQ
Shares (millions): 8.4
Price range $23.00 - $23.00
Est. $ Volume $193.2 mil
Manager / Joint Managers Goldman Sachs/ BofA Securities/ Evercore ISI
CO-Managers -
Expected To Trade: 12/11/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change